One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Orchestra BioMed Holdings, Inc.
OBIO · NGM · Healthcare · Biotechnology
Current price
$5.45
52-week range
$3.26 - $6.50
Market cap
$327.57M
Balance sheet
Healthy
-45.13x Concerning
Net cash $39.20M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Operating margin compressed from -924.3% to -25404.5% over 3 years.
- Risk Return on equity was -397.3% last year — the company lost money on shareholders' equity.
What this company does
Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. is a company developing medical treatments like devices to lower blood pressure and help with artery disease. Their money mainly comes from partnerships with larger medical companies like Medtronic and Terumo to develop and sell these new treatments. This matters because successful partnerships can bring in significant funding and help get their innovative medical products to patients who need them.
How the company got here
Orchestra BioMed Holdings was founded in 2017 and has since focused on developing innovative medical technologies. The company's strategy revolves around creating promising therapeutic product candidates and then partnering with larger, established medical device companies to bring them to market. This approach allows Orchestra BioMed to focus on innovation and clinical development while leveraging the commercial expertise and infrastructure of its partners. The company has secured significant partnerships with major players like Medtronic and Terumo Corporation, which are crucial for advancing its product pipeline and achieving global commercialization. This model aims to accelerate the delivery of new medical solutions to patients while optimizing development and commercialization costs.
What it actually does
Orchestra BioMed Holdings is a biomedical company that develops medical technologies designed to address significant unmet needs in healthcare. Instead of manufacturing and selling products directly, the company focuses on innovation and clinical development. It then partners with larger medical device companies to handle the manufacturing, marketing, and sales of these technologies. This business model, often referred to as a partnership-enabled approach, allows Orchestra BioMed to concentrate on research and development while sharing the risks and rewards with its collaborators.
BackBeat Cardiac Neuromodulation Therapy (CNT)
This business line focuses on developing BackBeat Cardiac Neuromodulation Therapy (CNT), also known as Atrioventricular Interval Modulation (AVIM) therapy. It's a bioelectronic treatment designed to help lower blood pressure (hypertension) by modulating the body's autonomic nervous system. The therapy is intended for patients who already have pacemakers, with the goal of integrating this technology into next-generation pacemaker devices. Orchestra BioMed has a strategic collaboration with Medtronic for the development and commercialization of this therapy, which represents a significant part of their innovation efforts.
Virtue Sirolimus AngioInfusion Balloon (SAB)
This segment involves the development of the Virtue Sirolimus AngioInfusion Balloon (SAB). This is a drug-device combination product candidate used to treat atherosclerotic artery disease, a condition where arteries become narrowed or blocked. The Virtue SAB is designed to deliver a medication called sirolimus to the artery wall during a procedure called angioplasty, which uses a balloon to open the blocked artery. Orchestra BioMed is working with Terumo Corporation on the development and commercialization of this product, aiming to provide a new treatment option for cardiovascular disease.
Other Minimally Invasive Surgical Devices
While the company's primary focus is on its two flagship therapies, Orchestra BioMed also has a history of developing other medical devices. These include products like the FreeHold devices, which assist in minimally invasive surgery, and the Pure-Vu system, a device designed to improve the cleansing of the gastrointestinal tract during endoscopic procedures. These products represent a smaller portion of the company's current development efforts compared to its cardiovascular-focused technologies.
What management is betting on now
Orchestra BioMed's management is primarily focused on advancing its two main product candidates, BackBeat CNT and Virtue SAB, through clinical trials and regulatory approvals. Their strategy hinges on their partnership model, where they collaborate with larger companies like Medtronic and Terumo to share development costs and leverage commercial expertise. Management believes this approach enhances capital efficiency and increases the likelihood of their innovations reaching patients globally. They are also exploring opportunities to expand their product pipeline through strategic collaborations and potential acquisitions.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-13.77M
FY2024 Q4
$-13.64M
FY2025 Q1
$-16.73M
FY2025 Q2
$-15.56M
FY2025 Q3
$-14.86M
FY2025 Q4
$-2.30M
FY2026 Q1
$-22.35M
FY2026 Q2
$-19.59M
Revenue
$88.00K
Net income
$-23.75M
Diluted EPS
-0.38
Operating cash flow
$-19.33M
Free cash flow
$-19.59M
Fetching…
Sources
Revenue
$110.00K
Net income
$-20.69M
Diluted EPS
-0.33
Operating cash flow
$-22.17M
Free cash flow
$-22.35M
Fetching…
Sources
Revenue
$30.92M
Net income
$6.25M
Diluted EPS
0.28
Operating cash flow
$-2.27M
Free cash flow
$-2.30M
Fetching…
Sources
Revenue
$861.00K
Net income
$-20.83M
Diluted EPS
-0.40
Operating cash flow
$-14.55M
Free cash flow
$-14.86M
Fetching…
Sources
Revenue
$836.00K
Net income
$-19.36M
Diluted EPS
-0.50
Operating cash flow
$-15.53M
Free cash flow
$-15.56M
Fetching…
Sources
Revenue
$868.00K
Net income
$-18.75M
Diluted EPS
-0.49
Operating cash flow
$-16.62M
Free cash flow
$-16.73M
Fetching…
Sources
Revenue
$253.00K
Net income
$-16.16M
Diluted EPS
-0.42
Operating cash flow
$-13.54M
Free cash flow
$-13.64M
Fetching…
Sources
Revenue
$987.00K
Net income
$-15.43M
Diluted EPS
-0.41
Operating cash flow
$-13.70M
Free cash flow
$-13.77M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $5.45
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $39.2M - more cash than debt. Interest coverage -45.1x.
Net debt
$-39.20M
Interest coverage
-45.13x
Orchestra BioMed Holdings, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
OBIO
BASELINE
Orchestra BioMed Holdings, Inc.
Total debt $70.76M Interest coverage -45.13x This is the baseline the peer rows are being compared against.
What you should know
The case for and against OBIO
0 Rewards
2 Risks
Rewards
Risks
-
Operating margin compressed from -924.3% to -25404.5% over 3 years.
-
Return on equity was -397.3% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-3.61x
P/B
16.98x
P/S
10.24x
EV/EBITDA
-5.48x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
99.5%
Operating margin
-25,404.5%
Net margin
-184.6%
ROE
-397.3%
ROA
-45.7%
Health
Liquidity and balance-sheet strength
Debt / equity
2.41x
Current ratio
8.26x
Quick ratio
8.17x
Total debt
$70.76M
Total cash
$109.96M
Growth
How the business has been compounding
Revenue TTM
$31.98M
Revenue 5Y CAGR
248.3%
EPS TTM
-0.86
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-58.32M
Free CF TTM
$-49.45M
FCF margin
-154.7%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—